84594-78-5

Usage

Uses

Used in Pharmaceutical Industry:
6-Nitro-2,3-Dihydrobenzofuran-5-Amine is utilized as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its presence in the molecular structure of target compounds can influence their therapeutic properties, making it a valuable component in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Nitro-2,3-Dihydrobenzofuran-5-Amine serves as a building block for the creation of agrochemicals, potentially enhancing crop protection and management through its incorporation into effective and targeted products.
Used in Organic Synthesis:
6-Nitro-2,3-Dihydrobenzofuran-5-Amine is employed as a versatile precursor in organic synthesis, allowing for the development of a range of organic compounds that can be applied across various industries, from pharmaceuticals to materials science.
Used in Antitumor and Antiviral Research:
6-Nitro-2,3-Dihydrobenzofuran-5-Amine has been studied for its potential antitumor and antiviral properties, making it a candidate for further research and development in the medical field. Its capacity to interact with biological targets may lead to the discovery of new therapeutic agents.
Safety Precautions:
It is crucial to handle 6-Nitro-2,3-Dihydrobenzofuran-5-Amine with care due to its toxic nature. Ingestion or inhalation can result in harmful effects, necessitating proper safety measures during its use in laboratories and industrial settings.

Upstream product

• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 81926-25-2 5-acetamido-2,3-dihydrobenzo<1,2-b>furan 
• 17403-47-3 5-nitro-2,3-dihydro-1-benzofuran 
• 42933-43-7 2,3-dihydro-1-benzofuran-5-amine 
• 496-16-2 2.3-dihydrobenzofuran 

Downstream Products

• 911300-51-1 6-nitro-2,3-dihydro-1-benzofuran 
• 1228880-71-4 5,6-diamino-2,3-dihydrobenzofuran 
• 57786-34-2 6-amino-2,3-dihydrobenzofuran 

Relevant academic research and scientific papers

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention relates to benzimidazole derivatives and their pharmaceutical compositions and uses, specifically to benzimidazole derivatives of Formula (I), or their stereoisomer, pharmaceutically acceptable salt or solvates thereof, in which R1, R2, R3, R4, R5 and n have the definitions in the description; the present invention further relates to a pharmaceutical composition containing the compounds, methods for preparing the compounds, and use of the compounds for manufacturing of a medicament for prophylaxis and/or treatment of peptic ulcer, ulcer hemorrhage and diseases associated with gastric acid.

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.